Somaxon Pharmaceuticals, Inc. (SOMX) Posts Q2 EPS Loss of $0.33,

Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) reported Q2 EPS of ($0.33), $0.03 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $6.2 million versus the consensus estimate of $3.79 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Financial stock slips 3% as Fixed Income, Asset Management revenues fall
• H.B. Fuller (FUL) Tops Q3 EPS by 5c, Misses on Revenue; Offers FY26 EPS Guidance
• Scholastic Corp (SCHL) Misses Q1 EPS by 23c